Evommune (EVMN) Assets (2024 - 2026)

Evommune's (EVMN) quarterly Assets came in at $322.5 million in Q1 2026, up 43.35% on a QoQ basis from $224.9 million in Q4 2025.

Evommune (EVMN) Assets (2024 - 2026) Analysis & Trends

Evommune (EVMN) has 3 years of Assets data on file, last reported at $322.5 million in Q1 2026.

On a quarterly basis, Assets changed N/A year-over-year to $322.5 million in Q1 2026; TTM through Mar 2026 was $322.5 million, a N/A change from a year earlier, with the FY2025 full-year figure at $224.9 million, up 195.77% from the prior year.
Assets for Q1 2026 stood at $322.5 million, up from $224.9 million in the prior quarter.
Over the last five years, Assets for EVMN reached as high as $322.5 million in Q1 2026 and fell as low as $76.1 million in Q4 2024.
Historically, Assets has averaged $177.0 million across 3 years, with a median of $154.7 million in 2025.
On a YoY basis, Assets climbed as much as 195.77% in 2025 and fell as far as 195.77% in 2025.
Year by year, Assets stood at $76.1 million in 2024, then soared by 195.77% to $224.9 million in 2025, then surged by 43.35% to $322.5 million in 2026.
Per Business Quant data, the three most recent Assets figures were $322.5 million in Q1 2026, $224.9 million in Q4 2025, and $84.5 million in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Assets (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	311.58 Mn
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	78.88 Mn
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	8.55 Bn
4	NuCana	279.75 Bn	279.75 Bn	-	39.68 Mn
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	26.48 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	40.87 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-	811.27 Mn
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	10.03 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	2.25 Bn
10	Evommune	381.48 Mn	170.02 Mn	-	322.46 Mn

Download Data